Exane Derivatives Acadia Pharmaceuticals Inc Transaction History

Exane Derivatives

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$15.78 - $24.77 $9,531 - $14,961	-604 Closed	0 $0
Q2 2021 Jul 28, 2021	BUY	$19.4 - $27.42 $11,717 - $16,561	604 New	604 $0
Q1 2021 Apr 30, 2021	SELL	$25.02 - $54.99 $137,735 - $302,719	-5,505 Closed	0 $0
Q4 2020 Jan 27, 2021	BUY	$41.04 - $56.79 $105,883 - $146,518	2,580 Added 88.21%	5,505 $0
Q3 2020 Oct 06, 2020	SELL	$36.42 - $57.0 $38,823 - $60,762	-1,066 Reduced 26.71%	2,925 $0
Q2 2020 Jul 10, 2020	SELL	$39.26 - $52.73 $28,542 - $38,334	-727 Reduced 15.41%	3,991 $0
Q1 2020 Apr 17, 2020	BUY	$31.65 - $46.87 $149,324 - $221,132	4,718 New	4,718 $0

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.02B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.